Sökning: WFRF:(Chene G)
> (2010-2014) >
Ritonavir-boosted d...
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
-
- Raffi, François (författare)
- University of Nantes
-
- Babiker, Abdel G. (författare)
- University College London
-
- Richert, Laura (författare)
- University of Bordeaux
-
visa fler...
-
- Molina, Jean-Michel (författare)
- Paris Diderot University,Saint-Louis Hospital, Paris
-
- George, Elizabeth C. (författare)
- University College London
-
- Antinori, Andrea (författare)
- Lazzaro Spallanzani National Institute for Infectious Diseases
-
- Arribas, Jose R (författare)
- University Hospital La Paz
-
- Grarup, Jesper (författare)
- University of Copenhagen,Copenhagen University Hospital
-
- Hudson, Fleur (författare)
- University College London
-
- Schwimmer, Christine (författare)
- University of Bordeaux
-
- Saillard, Juliette (författare)
- ANRS - France Recherche Nord & Sud Sida-HIV Hépatites virales
-
- Wallet, Cédrick (författare)
- University of Bordeaux
-
- Jansson, Per O. (författare)
- University of Copenhagen
-
- Allavena, Clotilde (författare)
- University of Nantes
-
- Van Leeuwen, Remko (författare)
- Academic Medical Center of University of Amsterdam (AMC),Amsterdam Institute for Global Health and Development
-
- Delfraissy, Jean-François (författare)
- Bicêtre Hospital
-
- Vella, Stefano (författare)
- Italian National Institute of Health (ISS)
-
- Chêne, Geneviève (författare)
- University of Bordeaux
-
- Pozniak, Anton (författare)
- Chelsea and Westminster Hospital
-
- Odermarsky, Michal (författare)
- Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine
-
visa färre...
-
(creator_code:org_t)
-
- 2014
- 2014
- Engelska 10 s.
-
Ingår i: The Lancet. - 1474-547X. ; 384:9958, s. 51-1942
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Standard first-line antiretroviral therapy for HIV-1 infection includes two nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs), but these drugs have limitations. We assessed the 96 week efficacy and safety of an NtRTI-sparing regimen.METHODS: Between August, 2010, and September, 2011, we enrolled treatment-naive adults into this randomised, open-label, non-inferiority trial in treatment-naive adults in 15 European countries. The composite primary outcome was change to randomised treatment before week 32 because of insufficient virological response, no virological response by week 32, HIV-1 RNA concentration 50 copies per mL or higher at any time after week 32; death from any cause; any new or recurrent AIDS event; or any serious non-AIDS event. Patients were randomised in a 1:1 ratio to receive oral treatment with 400 mg raltegravir twice daily plus 800 mg darunavir and 100 mg ritonavir once daily (NtRTI-sparing regimen) or tenofovir-emtricitabine in a 245 mg and 200 mg fixed-dose combination once daily, plus 800 mg darunavir and 100 mg ritonavir once daily (standard regimen). This trial was registered with ClinicalTrials.gov, number NCT01066962.FINDINGS: Of 805 patients enrolled, 401 received the NtRTI-sparing regimen and 404 the standard regimen, with median follow-up of 123 weeks (IQR 112-133). Treatment failure was seen in 77 (19%) in the NtRTI-sparing group and 61 (15%) in the standard group. Kaplan-Meier estimated proportions of treatment failure by week 96 were 17·8% and 13·8%, respectively (difference 4·0%, 95% CI -0·8 to 8·8). The frequency of serious or treatment-modifying adverse events were similar (10·2 vs 8·3 per 100 person-years and 3·9 vs 4·2 per 100 person-years, respectively).INTERPRETATION: Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL.FUNDING: European Union Sixth Framework Programme, Inserm-ANRS, Gilead Sciences, Janssen Pharmaceuticals, Merck Laboratories.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
Nyckelord
- Adenine
- Adult
- Anti-HIV Agents
- CD4 Lymphocyte Count
- Cholesterol, HDL
- Cholesterol, LDL
- Darunavir
- Deoxycytidine
- Drug Resistance, Viral
- Drug Therapy, Combination
- Emtricitabine
- Female
- HIV Infections
- HIV-1
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Organophosphonates
- Pyrrolidinones
- Raltegravir Potassium
- Ritonavir
- Sulfonamides
- Tenofovir
- Treatment Outcome
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Raffi, François
-
Babiker, Abdel G ...
-
Richert, Laura
-
Molina, Jean-Mic ...
-
George, Elizabet ...
-
Antinori, Andrea
-
visa fler...
-
Arribas, Jose R
-
Grarup, Jesper
-
Hudson, Fleur
-
Schwimmer, Chris ...
-
Saillard, Juliet ...
-
Wallet, Cédrick
-
Jansson, Per O.
-
Allavena, Clotil ...
-
Van Leeuwen, Rem ...
-
Delfraissy, Jean ...
-
Vella, Stefano
-
Chêne, Geneviève
-
Pozniak, Anton
-
Odermarsky, Mich ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Infektionsmedici ...
- Artiklar i publikationen
-
The Lancet
- Av lärosätet
-
Lunds universitet
-
Karolinska Institutet